Biosimilars are rapidly transforming the U.S. pharmaceutical market amid rising healthcare costs and a shift in interchangeability policy. Market competition is intensifying, with some biosimilars offering wholesale and ASP discounts, signaling significant cost savings and ultimately broader adoption.

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has developed are...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars...